Related references
Note: Only part of the references are listed.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment
Eleftheria Hatzimichael et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
Myeloproliferative neoplasms and personalized medicine: the perfect match?
Jean-Jacques Kiladjian et al.
HAEMATOLOGICA (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Myeloproliferative neoplasms and personalized medicine: the perfect match?
Jean-Jacques Kiladjian et al.
HAEMATOLOGICA (2015)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q)
Julia Turbiner Geyer et al.
HUMAN PATHOLOGY (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
M. Mallo et al.
LEUKEMIA (2011)
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation
Meritxell Nomdedeu et al.
LEUKEMIA RESEARCH (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
WHO-defined 'myelodysplastic syndrome with isolated del(5q)′ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
M. M. Patnaik et al.
LEUKEMIA (2010)
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation
Gemma Azaceta et al.
LEUKEMIA & LYMPHOMA (2010)
JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones
L. Sokol et al.
LEUKEMIA RESEARCH (2010)
JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia
A. Pich et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
W. Ingram et al.
LEUKEMIA (2006)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Share Paper
